Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Jaume CapdevilaNicola FazioCarlos LopezAlexandre TeuléJuan W ValleSalvatore TafutoAna CustodioNicholas ReedMarkus RadererEnrique GrandeRocio Garcia-CarboneroPaula Jiménez-FonsecaJorge HernandoAlberto BongiovanniFrancesca SpadaVicente AlonsoLorenzo AntonuzzoAndrea SpallanzaniAlfredo BerrutiAdelaida La CastaIsabel SevillaPatrizia KumpDario GiuffridaXavier MerinoLorena TrejoPablo GajateIgnacio MatosAngela LamarcaToni IbrahimPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
We report the highest centrally confirmed response reported to date with a multikinase inhibitor in advanced GEP-NETs, with a particularly strong response in the panNET cohort. This study provides novel evidence for the efficacy of lenvatinib in patients with disease progression following treatment with other TAs, suggesting the potential value of lenvatinib in the treatment of advanced GEP-NETs.